Efficacy and Toxicity of 177LuLu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data
Key Points
Key points are not available for this paper at this time.
Abstract
The phase 3 VISION trial demonstrated that [
Like
Bookmark
Share
Like
Bookmark
Share
Efficacy and Toxicity of 177LuLu-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer: Results from the U.S. Expanded-Access Program and Comparisons with Phase 3 VISION Data | Synapse